PAR-25-203
Focused Technology Research and Development (R01 Clinical Trial Not Allowed)
Summary
PAR-25-203: Focused Technology Research and Development (R01)
Research Focus
This program supports development of biomedical research technologies that have demonstrated proof-of-concept but require substantial technical innovation to reach prototype stage. NIGMS seeks applications focused exclusively on advancing tools, methods, and techniques—not on testing specific biological questions. Eligible technology outcomes include laboratory instruments and devices, algorithms and software, chemical reagents and processes, and engineered biological molecules or systems for use as research tools. Projects should address broad needs in biomedical research that exceed current technological capabilities, with the prototype representing a significant advance over the state of the art. Validation may use well-characterized test systems, but the project aims must remain focused entirely on technology development, not on answering biological research questions. Successful projects will produce functioning prototypes adequately characterized for first application to the biomedical research questions that motivated their development.
At a Glance
- Who can apply: Not stated (see NIH standard eligibility in Application Guide)
- Funding & project length: Not stated; projects should require 3–9 years of focused effort
- Award mechanism: R01 Research Project Grant (clinical trials not allowed)
- Key dates: Open January 5, 2025; rolling due dates through January 8, 2028; earliest start December 2025
- Best fit for: Researchers developing novel instruments, software, reagents, or engineered biological tools with preliminary proof-of-concept data and significant remaining technical hurdles; excludes disease-specific technology or incremental improvements
Key Facts
Deadline
Fri, January 7, 2028
Posted
Thu, November 14, 2024
Award / Year (direct costs)
$250,000
Max Total
$2,250,000
Max Duration
9 years
Keywords
Research Areas
Gotchas (6)
Applications proposing to test specific biological questions will be administratively withdrawn without review, even if they include technology development components
95%
Source Text
“Applications that do propose tests of specific biological questions are not responsive to this NOFO and will be administratively withdrawn without review.”
Projects must focus entirely on technology development with validation limited to test systems; any aims addressing specific biological questions trigger administrative withdrawal
95%
Source Text
“Applications that include aims that address specific biological questions are not responsive to the goals of this NOFO and will be administratively withdrawn without review.”
Technology must already have proof-of-concept and preliminary data; projects without prior proof-of-concept should go to the companion R21 (PAR-25-202) instead
95%
Source Text
“Applications to this NOFO should propose development of technologies that are already supported by proof-of-concept and preliminary data. The project focus should be on advancing the technology to a stage that demonstrates its potential for broad utility in biomedical research. Projects that develop new technologies that are not yet supported by proof of concept or feasibility data may be appropriate for PAR-25-202 (R21).”
Applicants must consult with Scientific/Research Contacts before submission to assess project fit; final responsiveness determination occurs after submission and can result in administrative withdrawa
90%
Source Text
“Prospective applicants are strongly advised to consult with the Scientific/Research Contact(s) listed in Part 2. Section VII. Agency Contacts for guidance on assessing the project's fit for this NOFO. Final determination of application responsiveness to this NOFO will be based on NIH Staff assessment of the full application after submission. Applications that are determined to be non-responsive to this NOFO, or that propose research topics that are not appropriate for NIGMS, will be administrati”
Clinical trial applications are explicitly not allowed per the title and mechanism specification
95%
Source Text
“PAR-25-203: Focused Technology Research and Development (R01 Clinical Trial Not Allowed)”
The NOFO emphasizes that projects should not be incremental improvements or obvious extrapolations of established technology. Applications with such characteristics will be lower priority or potential
90%
Source Text
“Applications with a focus on optimization, hardening, or obvious extrapolations of established technology will be a lower priority for funding. Projects supported by this program should not be incremental improvements to established technologies.”